This study is currently not recruiting participants.

I3Y-MC-JPBJ; A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY2835219 in combination with another anti-cancer drug in participants with Non-Small Cell Lung Cancer that is advanced or has spread to other parts of the body (stage IV).

Description

The main purpose of this study is to evaluate the safety of the study drug known as LY2835219 in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.

Details
Condition Lung Cancer
Age 18years - 100years
Clinical Study IdentifierTX3912
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.